GlobalData’s detailed strategic reports on the MFN executive order and on the GENEROUS model examined how some of the known ...

After signing a drug pricing deal with the White House, J&J will now offer some of its branded medicines at discounted rates ...

CDMOs are re-evaluating a reliance on China and increasingly turning to nearshoring and friendshoring for supply chain ...

With smart DMPK strategies, cross-domain collaboration, and strong CDMO support, companies are pushing past the challenges of ...

Takeda has announced a global collaboration and licence agreement with Halozyme to continue advancing vedolizumab with the ...

Santhera Pharmaceuticals has entered into an exclusive licensing agreement with Nxera Pharma for Agamree to treat DMD in ...

Alveus Therapeutics has debuted with $160m in Series A financing, as the biotech looks to join the crowded obesity sector ...

GSK will be filing for approval of bepirovirsen in hepatitis B to global regulatory authorities based on the Phase III data.

Day One Biopharmaceuticals has concluded its acquisition of Mersana Therapeutics after meeting all the tender offer ...

Octapharma has received approval from the US FDA for a new 2-g formulation of Fibryga for use in patients with AFD.

According to the registration form, Aktis intends to use a large portion of the IPO proceeds on the two programmes. Around ...

Takeda and Protagonist Therapeutics have jointly submitted a NDA seeking approval from the US FDA for rusfertide to treat ...